Unicycive Therapeutics Inc
UNCY
View Detailed Chart
6.110USD
-0.280-4.38%
Close 03/30, 16:00（ET）Quotes delayed by 15 min
88.58MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-4.38%
5 Days
-9.75%
1 Month
-12.59%
6 Months
+40.14%
Year to Date
+5.89%
1 Year
-0.49%
View Detailed Chart
TradingKey Stock Score of Unicycive Therapeutics Inc
Currency: USD Updated: 2026-03-27Key Insights
Unicycive Therapeutics Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 160 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 46.50.In the medium term, the stock price is expected to trend up.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Unicycive Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Unicycive Therapeutics Inc Highlights
StrengthsRisks
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -1.84, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 6.67M shares, decreasing 3.66% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 788.59K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of -0.79.
Analyst Rating
Based on
8
analysts
Buy
Current Rating
46.500
Target Price
+601.36%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Unicycive Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Unicycive Therapeutics Inc Info
Unicycive Therapeutics, Inc. is a biotechnology company developing treatments for kidney diseases. The Company's lead drug candidate, oxylanthanum carbonate (OLC), is an investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. Its second asset, UNI-494, is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury.
Ticker SymbolUNCY
CompanyUnicycive Therapeutics Inc
CEOGupta (Shalabh)
Websitehttps://unicycive.com/
Related Instruments
+0.96%
+1.56%
+0.85%
+2.90%
-1.28%
+1.78%
+1.47%
+0.07%
+0.00%
+2.70%
-2.08%
-0.13%
+0.72%
+2.03%
+2.33%
0.00%
+1.57%
-0.13%
+2.63%
+2.01%Popular Symbols
246.630
-2.170 (-0.87%)
165.170
-2.350 (-1.40%)
67956.690
+1335.290 (+2.00%)
251.670
-23.670 (-8.60%)
2073.150
+52.450 (+2.60%)
355.280
-6.550 (-1.81%)
4573.060
+62.280 (+1.38%)
101.051
-3.211 (-3.08%)
1.148
+0.001 (+0.11%)
159.636
-0.023 (-0.01%)
